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Background. Sepsis is defined as a life-threatening organ dysfunction due to a dysregulated host response to infection. Sepsis is
the dominant cause of acute kidney injury (AKI), accounting for nearly 50% of episodes of acute renal failure. Signaling cascades
and pathways within the kidney are largely unknown and analysis of these molecular mechanisms may enhance knowledge on
pathophysiology and possible therapeutic options. Material and Methods. 26 male Wistar rats were assigned to either a sham
group (control, 𝑁 = 6) or sepsis group (𝑁 = 20; cecal ligature and puncture model, 24 and 48 hours after CLP). Surviving
rats (𝑛 = 12) were decapitated at 24 hours (early phase; 𝑛 = 6) or 48 hours (late phase; 𝑛 = 6) after CLP and kidneys removed
for proteomic analysis. 2D-DIGE and DeCyder 2D software (𝑡-test, 𝑃 < 0.01) were used for analysis of significantly regulated
protein spots. MALDI-TOF in combination with peptide mass fingerprinting (PMF) as well as Western Blot analysis was used for
protein identification. Bioinformatic network analyses (STRING, GeneMania, and PCViz) were used to describe protein-protein
interactions. Results. 12 spots were identified with significantly altered proteins (𝑃 < 0.01) in the three analyzed groups. Two spots
could not be identified. Four different proteins were found significantly changed among the groups: major urinary protein (MUP5),
cytochrome c oxidase subunit B (COX5b), myosin-6 (MYH6), and myosin-7 (MYH7). A significant correlation with the proteins
was found for mitochondrial energy production and electron transport. Conclusions. COX5B could be a promising biomarker
candidate since a significant association was found during experimental sepsis in the present study. For future research, COX5B
should be evaluated as a biomarker in both human urine and serum to identify sepsis.
1. Introduction
Sepsis has been recently defined as a life-threatening organ
dysfunction due to a dysregulated host response to infection
[1]. It is characterized by a specific set of systemic reactions
to overwhelming infection [1, 2]. During clinical course,
sepsis is often seriously complicated by renal dysfunction and
triggers highmortality [3, 4], being the leading cause of death
in critically ill patients [5].
The kidney shows extreme metabolic activity and an
adequate energy supply is a prerequisite for its multiple
functions [6]. Furthermore, sepsis is the dominant cause of
acute kidney injury (AKI), accounting for nearly 50% of
episodes of acute renal failure [7, 8]. AKI has been a common
and severe problem in critically ill patients during the last
decade [9]. Between 5% and 20% of critically ill patients in
the intensive care unit (ICU) have at least an episode of AKI
[9]. Early identification of those patients at risk for AKI could
help clinical decision making [10].
Acute reduction in renal function during sepsis arises
from a combination of local ischemia, inflammation, and
additional factors [8, 11]. Sepsis-affected signaling cascades
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and pathways within the kidney are largely unknown. More
than 1 million different protein variants are present in the
mammalian organism, whose cellular abundance, functional
status, and localization vary over time and are influenced by
numerous environmental interactions [12]. However, analysis
of these molecular mechanisms may enhance knowledge on
pathophysiology and possible therapeutic options but may
also suggest possible biomarker candidates to identify sepsis
early in the clinical course. Unfortunately, patients’ kidneys
are typically not usable for those analyses. Consequently,
animal models are commonly used as replace.
During the last decade, proteomics has increasingly been
applied to identify and quantify mitochondrial proteins
related to cellular perturbations, which enforce and elaborate
data from metabolites and gene sequences, for example, in
human mitochondrial disorders [12]. A proteomic approach
for identification, quantification, and characterization of pro-
teins of interest in biological materials facilitates understand-
ing the pathogenesis. This approach has been extensively
used for several diseases, for example, in sepsis [13–16],
hyperoxia [17–19], cancer [20], liver diseases [20, 21], cardiac
diseases [22, 23], neurodegenerative diseases [24, 25], and
renal research [26].
Although understanding pathophysiology of sepsis is
expected to have amarked impact on the development of new
effective treatment strategies, underlying molecular mecha-
nisms of renal dysfunction in sepsis are still largely unknown
[7]. Furthermore, there are currently no strong biomarkers
specifically linked to valid prediction and outcome of sepsis-
induced acute kidney failure [27, 28] that could guide a
prompt tailored therapy. The exact mechanisms involved are
still not clear, due to difficulties to obtain histological data
or biochemical kidney function marks in the different sepsis
phases [9].
The present study investigates changes of protein expres-
sion in kidney tissue in a cecal ligature and puncture (CLP)
model of rat sepsis during a time-course of 24 or 48 hours
after sepsis induction. More specifically, proteomic analysis
was performed between kidney tissues of healthy rats and
CLP sepsis rats (24 hours or 48 hours, resp.). These findings
were analyzed and compared in the context of bioinfor-
matic protein-interaction analyses. Because proteins are vital
molecules in normal biological or pathological functions,
analysis of all proteins (i.e., the proteome)may clarify the role
of specific proteins and possible protein-protein interactions
in AKI [29].
2. Materials and Methods
2.1. Animal Treatment. Upon approval by the local insti-
tutional review board (Regierungspraesidium Karlsruhe,
Germany), experiments were performed according to the
regulations of the National Institutes of Health Guide
for the Use of Laboratory Animals. Male Wistar rats
(Charles River Deutschland, Sulzfeld, Germany) were kept
under temperature controlled environmental conditions
at 22∘C on a 14-hour light followed by a 10-hour dark
cycle prior to the experiments and were fed a stan-
dard diet (Altromin C1000, Altromin, Lage, Germany)
with free access to food and water. Animal treatment
was performed as previously published in other trials
[13–15].
2.2. Study Groups. A total of 26 rats weighting 330 ± 10 g
standard deviation (SD) were used for this study. Six rats
ware assigned to a sham group without cecal ligature and
puncture (CLP, control group). Based on mortality results
from our laboratory [13], 20 rats were assigned to the sepsis
group receiving CLP. Eight rats died before 24 hours and 12
rats were assigned to two different sepsis groups (euthanasia
after 24 and 48 hours, resp.) being used for proteomic
analysis.
2.3. Sepsis Model. For the induction of sepsis, the CLP
model [30, 31] was used as previously described [13–15]. On
the day of surgery, animals were randomly assigned to the
defined sepsis or sham group. Rats were anesthetized under
spontaneous breathingwith sevoflurane (1MAC) in a gaseous
mixture of 30% oxygen and 70% nitrous oxide.
After weighing, animals of the sepsis group underwent
laparotomy and ligation of the cecum (CLP) just below the
ileocecal valve with double punctures (18 gauge needle) at
the antimesenterial wall. One mm3 of feces was manually
squeezed out of the intestines in each rat. Thereafter, the
abdominal wall was closed in two layers.
Rats in the sham group underwent laparotomy with
cecum exenteration but without cecal ligation or puncture.
For fluid restoration due to anaesthesia, 10mL/kg of 0.9%
NaCl was injected subcutaneously. In both groups, anaes-
thesia was terminated, and the rats were allowed to recover.
Thereafter, food and water were freely available.
Depending on the group assignment, rats were reanes-
thetized as described above at the defined time points
of the experiments (24 or 48 hours after surgery) and
underwent both blood and organ removal after decapita-
tion in deep anaesthesia. After a lateral thoracotomy of
both sides the heart was exposed and at least 5mL of
blood was obtained by direct cardiac puncture for bacte-
rial analysis (blood culture BACTECTM PEDS-bottle, cul-
tivation on blood agar, boiled blood agar, and McConkey
media, BD PhoenixTM automated microbiology system,
Becton Dickinson Diagnostic Systems, Franklin Lakes, NJ,
USA), arterial blood gases, electrolytes, haemoglobin (Bayer
Vital Diagnostics, Rapidlab 865, Fernwald, Germany), blood
cell count (Advia 60, Bayer Vital Diagnostics, Fernwald,
Germany), albumin, and phosphate (bromocresol green,
ammonium molybdate, Advia 2400, Bayer Vital Diagnos-
tics, Fernwald, Germany). Physiological markers of rats are
depicted in Table 1. The kidneys were removed as quickly
as possible for proteomic analysis, frozen in isopentane
prechilled to −40 to −50∘C, and stored at −80∘C for further
analysis.
2.4. Sample Preparation. The following techniques andmeth-
odologies to identify altered proteins, including samples
preparation, 2D-DIGE, and PMF, were performed by TopLab
(Martinsried, Germany), being certified ISO 9001:2008.
Briefly, the following steps were performed.
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Each frozen kidney was weighed and those from each
experimental condition were pooled and grinded with liquid
nitrogen in mortar. The tissue powder of the pooled samples
was mixed with 4mL of lysis buffer [7M urea, 2M thiourea,
4% CHAPS, 30mM Tris pH 8.5, Roche complete protease
inhibitor cocktail, 1.2% Pefablock SC protease inhibitor,
1% Sigma phosphatase inhibitor cocktail 2, and 1% Sigma
phosphatase inhibitor cocktail 3] and transferred into a 15mL
reaction tube. Cells were lysed and proteins dissolved using
vigorous vortexing and sonication with a pulse of 1min
on ice. For sonication, portions of ∼0.8mL of each sample
were treated with a pulse of 1min using a Branson Sonifier
Ultrasonic cell disruptor with an ice chilled thermostat.
Samples were vortexed, incubated 5min on ice, and cen-
trifuged for 15min at 20,000×g to pellet debris and insoluble
material. The supernatant was taken for further analysis and
proteomics.
The protein concentration of samples was determined
using a Bradford assay [32]. According to the protein deter-
mination results with Bradford assay, 150 𝜇g protein of each
sample was diluted with labeling buffer [30mM Tris, pH 8.5;
7Murea; 2M thiourea; 4%CHAPS; Roche complete protease
inhibitor cocktail; Pefablock SC protease inhibitor] to a final
volume of 450 𝜇L. The samples were rebuffered with labeling
buffer using Vivaspin 500 ultrafiltration devices with a cut-
off of 5 kDa. After volume reduction samples were present in
100 𝜇L labeling buffer at last with a protein concentration of
5mg/mL.
2.5. DIGE Labeling. 65 𝜇g of the samples control and sepsis
48 h treatment was labeled with Cy3 and 65 𝜇g of the samples
control and sepsis 24 h treatment was labeled with Cy5.
Additionally, 50𝜇g of each sample was pooled as the internal
standard sample (Pool-A) and 65 𝜇g (13 𝜇L) of this mixture
was used for each labeling reaction with Cy2. For each label-
ing reaction with Cy2, Cy3, and Cy5 65 𝜇g protein (13 𝜇L) was
applied to 400 pmol CyDye.The reactionswere performed on
ice for 30min and stopped by adding lysine and incubating
for another 10min. Labeling was performed according to the
manufacturer’s protocol (FluoProbes/InterChim: 2-D DIGE
Cy5/3/2 Labeling kit). The labeling chemistry is based on
minimal labeling of lysine residues of the proteins, with one
lysine residue labeled per protein on average [33].
After labeling, reactions to run in the same 2D-DIGE
gel were pooled. The final volume of each sample was
adjusted to 100 𝜇L with lysis buffer B [7M urea; 2M thiourea;
4% CHAPS; Roche complete protease inhibitor cocktail;
Pefablock SC protease inhibitor] and samples were supple-
mented with 2% Servalyte and 1% DTT. Finally, 350 𝜇L of
rehydration buffer [6M urea; 2M thiourea; 2% CHAPS; 1%
DTT; 1 v/v% Servalyte 3–10 Iso-Dalt for 2D, Roche complete
protease inhibitor cocktail; Pefablock SC protease inhibitor]
was added to each sample.
2.6. 2D-DIGE. For the 2D-DIGE experiment, samples were
loaded directly after labeling onto two 24 cm IPG strips pH
3–10NL from Serva (𝑇 = 4%, 𝐶 = 2.7%) using passive in-
gel-rehydration for sample application. Therefore, the IPG
strips were rehydrated with 450𝜇L sample for 16 hours at
room temperature. Isoelectric focusing (IEF) was performed
for 100 kVh in total. All stepswere limitedwith 75𝜇Aper strip
and performed at 20∘C. The applied instrument was an IEF
100 focusing unit from Hoefer.
Protein separation in the second dimension was carried
out on precast 2D HPETM gels (𝑇 = 12.5%, 𝐶 = 2.7%) with
a SDS-GLYCIN-TRIS buffer system overnight (SDS, sodium
dodecyl sulfate). A molecular weight standard, commercially
available from Serva, was previously labeled with Cy2. The
standard comprising masses corresponding to 97, 67, 45, 29,
21, 12.5, and 6.5 kDa. respectively, was applied to the gel and
positioned next to the IPG strips. The two 2D-DIGE gels
were run in parallel (HPETM FlatTop Tower from Serva with
a Multi-TempIII Thermostatic Circulator and a HPE-Power
Supply 1500).
2.7. Image Analysis and Spot Significance. To visualize the
labeled and separated proteins after electrophoresis, the 2D-
DIGE gels were scanned at a resolution of 100 𝜇m with a
Typhoon FLA 9500 (GE Healthcare).
For image analysis, scan files of the 2D-DIGE gels were
loaded into DeCyder 2D software (GE Healthcare, version
7.2). Spots were detected with an estimate of 5,000 spots for
the 2D-DIGE gel. Subsequently, a detection area excluding
the region of strip application, molecular weight marker,
and running front was defined. Spots with a volume below
100,000 were defined to be background. Stained crumbs
originated from the Dyes were eliminated by excluding spots
with an area below 350. False positive spots, for example,
produced by dye artefacts within the gel were removed
manually. After the editing the gels were normalized towards
the Cy2 channel (internal standard).
2.8. Statistical Analysis and Data Handling. Spot IDs were
allocated to each spot detected and matched in the two 2D-
DIGE gels. An average ratio of spot volumes from different
samples was calculated for each spot ID. In case a value
of 3.0 was calculated for the average ratio, this means
the spot volume did increase three times compared to the
reference; an average ratio of−3.0means a threefold decrease.
Unchanged spot volumes have ideally an average ratio of
1.0.
The values of 2-fold SD (twice standard deviation) and
the corresponding thresholds of spot volumeswere calculated
and documented (Table 1). Using filter settings for these
threshold values differences in the spot volumes between two
samples were identified.
Subsequent image analysis with DeCyder software was
performed to determine differences between the samples.The
calculation was based on spot volumes after normalization
with the signals from the internal standard sample. Based
on the total spot number of detected spots and the standard
deviation, DeCyder 2D software calculates the threshold of
regulation. In case a spot volume of a certain spot in one
sample equates the 𝑥-fold of the spot volume in a second
sample, this spot is regulated if 𝑥 is above the threshold of
regulation (𝑥 > +threshold or 𝑥 < −threshold).
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Table 1: Physiological markers of rats in both groups analyzed. Data is presented as means. Fishers’ exact test was used for statistical analysis.
n.s.: not significant; bold-type numbers are significantly different from control.
Marker Control/sham group 24-hour sepsis group 48-hour sepsis group 𝑃 value
CRP, c-reactive protein [ng/𝜇L] 2.0 2.0 2.0 n.s.
WBC, white blood cells [/𝜇L] 3.2 2.3 2.8 𝑃 < 0.05
Ery, erythrocytes 6.1 6.6 6.6 n.s.
Hb, haemoglobin level 13.3 13.2 13.9 n.s.
Hk, hematocrit [%] 0.37 0.38 0.40 n.s.
MCV, mean corpuscular volume 59 58 57 n.s.
MCH, mean corpuscular
haemoglobin 22 21 20 n.s.
PLT, platelets [103/𝜇L] 818 400 456 𝑃 < 0.05
Using DeCyder 2D software, the normalized spots were
matched and the gel images were grouped according to the
samples loaded on the gels. Comparison of the samples was
performed using the 2 SD threshold combined with student’s
𝑡-test. Differences between the samples were defined to be
significant if the average ratio of the spot volumes was above
or below the threshold for 2 SD and the spot did pass the
students 𝑡-test (𝑃 = 0.01).
2.9. Protein Identification. We chose to compare the protein
expressions between the samples taken 24 and 48 hours
after completion, as well as between sepsis treated samples
(grouping the gels of sepsis 24 h treatment and sepsis 48 h
treatment) and control sample.
Specific protein spots were identified with peptide
mass fingerprinting (PMF) using tryptic in-gel digestion
and MALDI-TOF-MS. The spots were manually excised
and destained using an acetonitrile containing buffer. In-
gel digestion was performed overnight with 0.006–0.02𝜇g
trypsin (Serva, sequencing grade, cat. number 37283) in
10mM NH
4
HCO
3
buffer. Peptides were cocrystallized with
matrix (10mg/mL 𝛼-cyanohydroxy-cinnamic acid) onto the
MALDI target. Measurement was performed with a 4800
MALDI-TOF/TOF Analyzer (AB Sciex, Framingham, MA,
USA) using positive reflector mode (detection range 𝑚/𝑧
700–4500).
Raw data were processedwithGPS Explorer software (AB
Sciex, Framingham, MA, USA). All spectra were externally
calibrated using a peptide calibration standard.Themeasured
monoisotopic peptide masses were compared to all Rattus
sequences of the SwissProt database (7,928 rat sequences,
updated December 2014) using the software MASCOT
(Matrix Science, London, UK).
In order to obtain enough material for analysis with mass
spectrometry, a preparative 2D-gel loaded with a mixture of
control and sepsis samples of 24 h and 48 h treatment was
produced and stained with colloidal Coomassie.
2.10. Bioinformatic Network Analysis and Protein Func-
tions Analysis. To identify relevant pathways involved and
to describe the interactions and functions of our find-
ings, STRING 10 (Search Tool for Retrieval of Interacting
Genes/Proteins, http://string-db.org/), GeneMANIA (http://
www.genemania.org/), the KEGG database (Kyoto Ency-
clopedia of Genes and Genomes, http://www.genome.jp/
kegg/), and Pathway Commons (http://www.pathwaycom-
mons.org/) were used.
STRING 10 is a web-server database that provides predic-
tion and information about functional interactions between
proteins in form of networks [34, 35]. Predictions are based
on systematic genome comparisons that consider conserved
genomic neighborhood, gene fusion events, cooccurrence of
genes across genomes, and coexpression in other species [36].
Furthermore, published indexed articles, experimental data,
and knowledge of manually curated databases are taken into
account for the prediction [34].
To assess the likelihood of the prediction (level of con-
fidence), STRING 10 matches and calibrates findings with
KEGG pathways database knowledge as a reference [34, 36].
At the end of these events, a score indicates the level of
confidence, with the highest confidence set at 0.900, high
confidence at 0.700, medium confidence at 0.400, and low
confidence at 0.150. This final score results by combination
of the scores regarding the other parameters considered
(genomic neighborhood, gene fusion, etc.).
Search terms are typed in the box of the web tool,
one per line, and the depicted pathway can be adjusted
(managing someparameters as level of confidence, number of
interactions, etc.) to have the desired view of the interactions
and information. Similarly to STRING, GeneMANIA is a
tool that helps to predict interactions and function of list of
genes in form of network and, when available, of pathway
[37, 38]. Algorithms and data sources are different, but the
major difference with STRING is that GeneMANIA gives
the possibility of better customizing the network, allowing
the choice of data sources or highlighting specific functions,
with a more comfortable graphic experience [37]. It is
developed and continually updated by the University of
Toronto and is funded by the Ontario Ministry of Research
and Innovation. GeneMANIA knowledge is based on data
from large databases, which comprehend Gene Expression
Omnibus, BioGRID, EMBL-EBI, Pfam, Ensembl, Mouse
Genome Informatics, the National Center for Biotechnology
Information, InParanoid, and PathwayCommons [37, 38]. As
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these software programs use different algorithms, we chose to
perform the bioinformatics analysis with all of them in order
to retrieve the highest number of predicted interactions,
maintaining an acceptable level of confidence (0.400). KEGG,
one of the largest existing library of genes and network
[39], is organized in three databases: one for the genes of
all completed genomes (GENES database); one for func-
tional information, as cellular process, depicted as manually
curated functional pathways (PATHWAYSdatabase); and one
for enzymes and enzymatic reactions (LIGAND database)
[39].
Pathway Commons (PCViz) is a collection of publicly
available pathway information frommultiple organisms [40].
It provides researchers with convenient access to a com-
prehensive collection of biological pathways from multiple
sources represented in a common language for gene and
metabolic pathway analysis. Access is via a web portal for
query and download. Pathways can include biochemical
reactions, complex assembly, transport and catalysis events,
physical interactions involving proteins, DNA, RNA, small
molecules and complexes, gene regulation events, and genetic
interactions involving genes.
Pathway Commons integrates a number of pathway
and molecular interaction databases supporting BioPAX
and PSI-MI formats into one large BioPAX model, which
can be queried using the web API. This API can be used
by computational biologists to download custom subsets
of pathway data for analysis or can be used to incorpo-
rate powerful biological pathway and network informa-
tion retrieval and query functionality into websites and
software.
2.11. Western Blot Analysis. For the 1D SDS PAGE analysis,
the specific samples were diluted to a concentration of
10 𝜇g/𝜇L with HPLC water. Subsequently, a further dilution
step to 1.5 𝜇g/𝜇L with HPLC water was performed. To each
of the six diluted samples an equal volume of 3x SDS sample
buffer [30% glycerol; 187.5mMTris pH 6.8; 6% SDS, 3%DTT]
was added. Samples were boiled for 10min at 90∘C.
For protein separation a precast Tris-Glycine Gel 𝑇(%)
4–20 from Serva (SERVAGel TG 4–20) was used. A total
protein amount of 100 𝜇g and 15 𝜇g of each of the three
samples was loaded, by applying 20 𝜇L of the prepared
dilutions. To estimate the molecular weight of the proteins
and to check transfer efficiency 5 𝜇L of a prestained marker
(Serva Triple Color protein standard III) and twice 5 𝜇L
of an unstained protein marker (Protein test mixture 6,
Serva) were also loaded. Lanes without protein load were
filled with 1x sample buffer instead to ensure an even gel
run.
The gel run was started at low power for 10min a
10mA/gel. The main separation took place at 25mA/gel with
the current limited at 500V. After 110min (284Vh) the dye
front was about 5mm above the rear of the gel and the gel
run was stopped.
In order to transfer the proteins from the SDS gel onto
a polyvinylidene fluoride (PVDF) membrane a Trans-Blot
SD Semi-Dry Electrophoretic Transfer Cell from BioRad and
a discontinuous buffer system according to Khyse-Andersen
was used. Therefore three sheets of blotting paper (Schle-
icher & Schuell) and the gel were incubated for 5–10min
in cathodic transfer buffer (0.04M 6-aminohexanoic acid
(epsilon-aminocaproic acid), 20% isopropanol, and 0.01%
SDS). One further sheet of blotting paper was incubated
in anodic buffer I (0.3M Tris, 20% isopropanol) and three
sheets were incubated in anodic buffer II (0.025M Tris, 20%
isopropanol). The PVDF membrane was activated for 10 s
withmethanol and then incubated in cathodic transfer buffer.
A glass pipette was carefully used as a rolling pin when
assembling the blot to remove air bubbles from the sandwich.
For the transfer 5mA per cm2 membrane was applied. The
transfer was performed overnight at 4∘C. Protein transfer was
checked by staining the PVDF membrane with Ponceau S
and the blotted gel was additionally stained with colloidal
Coomassie to visualize the amount of proteins remaining in
the gel after transfer.
For blocking 10% BSA in TBS-T [20mM Tris pH 7.6;
155mM NaCl; 0.05% Triton-X 100; 10% BSA] was used
and the membrane was incubated for 1 h at RT. Incubation
with primary antibody (Anti-COX5B antibody [16H12H9]
ab110263) was performed in TBS-T/2% BSA [20mM Tris pH
7.6; 155mM NaCl; 0.05% Triton-X 100; 2% BSA] for 42 h at
+4∘C. The antibody was diluted to 1 𝜇g/mL. Subsequently,
the membrane was washed three times for 10min at RT with
TBS-T [20mM Tris pH 7.6; 155mM NaCl; 0.05% Triton-X
100]. The secondary antibody (HRP-conjugated Anti-Mouse
IgG produced in rabbit, Sigma-Aldrich A9044) was diluted
1 : 100,000 in TBS-T/2% BSA and applied for 1 h at RT.
Thereafter the membrane was washed three times for 10min
at RT with TBS-T and once for a few minutes with deionized
water. The horseradish-peroxidase-coupled antibody (HRP)
was visualized using an enhanced chemiluminescence (ECL)
substrate kit fromThermo Fisher (Super Signal West Femto)
and the signals were detected with a charge-coupled device
(CCD) camera system.
After signal acquisition the membrane was frozen at
−20∘C until further processing. The next day, the mem-
brane was thawed and stripped from the previously applied
antibodies by incubation for 30 seconds with prewarmed
stripping buffer [62.5mM Tris HCl pH 6.8, 2% SDS, and
100mM DTT]. Subsequently the membrane was extensively
washed with water and blocked with 10% BSA in TBS-T
[20mM Tris pH 7.6; 155mM NaCl; 0.05% Triton-X 100; 10%
BSA] for 1 h at room temperature.
As control and to check for equal protein load, anti-
alpha tubulin antibody was used as an internal loading
control. Incubation with primary antibody (anti-alpha tubu-
lin antibody [EP1332Y], Microtubule Marker, ab52866) was
performed in TBS-T/2% BSA [20mM Tris pH 7.6; 155mM
NaCl; 0.05% Triton-X 100; 2% BSA] for 42 h at +4∘C. The
antibody was diluted 1 : 50,000. Subsequently, the membrane
was washed three times for 10min at RT with TBS-T
[20mM Tris pH 7.6; 155mM NaCl; 0.05% Triton-X 100].
The secondary antibody (HRP-conjugated anti-rabbit IgG,
Molecular Probes, G21234) was diluted 1 : 7,000 in TBS-T/2%
BSA and applied for 1 h at RT. Thereafter the membrane was
washed three times for 10min at RT with TBS-T and once
for a few minutes with deionized water. The HRP-coupled
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Figure 1: (a) Preparative 2D-Gel (Coomassie blue) of control and sepsis samples. Threshold of regulation is 2 SD (standard deviation) and
𝑡-test value 𝑃 < 0.01. Spots #381 and #2110 have not been analyzed (Table 2) since they were too weak or not visible for excision. Other spots
are marked with arrows and numbers. Alteration of the spots is presented in Table 3. The gel is a sample gel with proteins of the 24 hours’
group. (b) Cy3 and Cy5 images of the gels. Cy5: red color = sepsis 24 h group. Cy3: green color = control group.The gel shows proteins of the
control group and 24 hours group. (c) Cy3 and Cy5 images of the gels. Cy5: red color = control group. Cy3: green color = 48 h sepsis group.
The gel shows proteins of the control group and 48 hours’ group.
antibody was visualized using an ECL substrate kit from
Thermo Fisher (Super Signal West Femto) and the signals
were detected with a CCD camera system.
3. Results
𝑁 = 26 male Wistar rats were used for the present study.
𝑁 = 6 rats were treated with sham surgery and served as
controls (healthy rats), and 𝑁 = 20 underwent CLP for
sepsis induction. Of these 20 rats, 𝑁 = 8 died before the
experiments and𝑁 = 6 were sacrificed 24 h after CLP (inter-
mediate sepsis) and𝑁 = 6were sacrificed 48 h after CLP (late
sepsis). White blood cell (WBC; 3.2 ∗ 109/𝜇L versus 2.3 ∗
109/𝜇L and 2.8 ∗ 109/𝜇L; 𝑃 < 0.05) count and platelet count
(PLT; 818 ∗ 103/𝜇L versus 400 ∗ 103/𝜇L and 456 ∗ 103/𝜇L)
differed significantly between the sepsis and control group
(Table 1).
3.1. 2D-DIGE Analysis. With the present technique, more
than 1.500 different spots were identified on the gels using
the 2D-DIGE analysis with DeCyder 2D. After specific
calculations by DeCyder 2D, a total of 12 spots was different
expressed in the groups/gels analyzed (Figures 1(a)–1(c)).
Seven protein spots were discovered to be differently
present between 24 h sepsis and 48 h sepsis. 𝑁 = 5 of these
spots were higher and abundant in the 24 h sample sepsis; the
other two protein spots were higher and abundant in the 48 h
sample sepsis (Table 2). From analysis between sample and
themixture of samples from24 h sepsis and 48 h sepsis,𝑁 = 5
different protein spots, all of them in higher abundance in the
control sample, were found (Table 2).
Oxidative Medicine and Cellular Longevity 7
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Table 3: Identified and significantly regulated protein spots and changes at 24 hours and 48 hours after sepsis induction as compared to
control. (↑) = upregulated protein; ↑ = highly upregulated protein; (↓) = downregulated protein; ↓ = highly downregulated protein.
Protein abbreviation Protein name Spot number 24 hours versus control 48 hours versus control
MYH6 Myosin-6 57 (↑) ↑
73 (↑) ↑
MYH7 Myosin-7 71 (↑) ↑
COX5B
Cytochrome c oxidase
subunit 5B,
mitochondrial
2494 (↑) ↑
MUP5 Major urinary protein
2327 ↓ ↓
2340 (↓) ↓
2346 ↓ ↓
2498 ↓ ↓
2507 ↓ ↓
3.2. Preparative 2D-Gel Analysis. Subsequent analysis with
DeCyder 2D of the preparative 2D-gel analysis (grouping
the samples of the three groups) found 11 protein spots
corresponding to that found with the previous 2-DIGE
analyses (Table 2). Of these, two protein spots, ID 381 and
ID 2110, belonging to sepsis samples, were not clearly visible
and, therefore, were not excised for protein identification.
Hence, a total of 9 spots, 4 higher and abundant in control
sample, 3 higher and abundant in 48 h sepsis, and 2 higher
and abundant in 24 h sepsis, were considered for protein
identification by PMF and were matched through MASCOT
software with SwissProt database for the identification.
3.3. Protein Identification. In the four spots found higher
and abundant in the control sample (ID 2346, ID 2507, ID
2327, and ID 2498), major urinary protein (“MUP5” for the
STRING database) was identified. MUP5 was detected also
in spot ID 2494 that was found higher and abundant in 24 h
sepsis. In the other spot overpresent in 24 h sepsis, ID 2494,
cytochrome c oxidase subunit B (“COX5B”) was recognized.
In three spots found higher and abundant in 48 h sepsis,
myosin-6 (“MYH6”) from spots ID 57 and ID 73 andmyosin-
7 (“MYH7”) from spot ID 71 were identified. Table 3 shows
alterations of protein expression in the specific groups (24
hours or 48 hours) as compared to control. For the fiveMUP5
spots and COX5B, expression was downregulated at both
time points and for MYH6 and MYH7 it was upregulated as
compared to control (Figure 3 and Table 3).
3.4. Bioinformatic Networks Analyses. STRING 10, GeneMA-
NIA, and PCViz were used for separate network analysis.
Using the STRING software, COX5B and MYH6 were found
to belong to two separated networks but linked with a level of
confidence of 0.508 through cytochrome c oxidase subunit
6 A2 (COX6A2) and actinin alpha 2 (Actn2) (Figure 3,
Tables 3 and 4). MUP5 does not present any connection
with these networks (Figure 3). COX5B is likely functionally
linked to the others subunits of cytochrome c oxidase, NADH
dehydrogenase, and ATP synthase, all the connections with a
very high level of confidence > 0.990 (Figure 3).
Myosins 6 and 7 were found to be strongly linked to the
other proteins of the muscle contraction (troponin I, actin,
tropomyosin alpha-1, and alpha-4 chain), all with a level of
confidence > 0,960 (Figure 3).
Using GeneMANIA and PCViz for analysis, significant
correlation of the identified proteins with other network
proteins was found.MYH6 andMYH7were linked especially
to other myosin and contractility proteins (Figures 4 and 5).
COX5B was found to be linked to 13 other network proteins
(Figure 4) as well as to a human cytochrome c protein (CYCS,
Figure 6).
3.5. Course of Sepsis: 24 versus 48 Hours after CLP. As
compared to the early phase of sepsis (24 hours after CLP),
MYH6 (avg. ratio −11.87 and −12.61) and MYH7 (avg. ratio
−11.88) were significantly overexpressed in the late phase of
sepsis (48 hours afterCLP, Table 2).However,MUP (avg. ratio
+8.19) andCOX5B (avg. ratio +7.67)were less expressed in the
late phase of sepsis (Table 2). Localization ofCOX5B ismainly
from the mitochondrion or intercellular space (Figure 7).
3.6. Pathways and Signaling Cascades. Using the pathway
analysis tool by http://www.genecards.org/, several pathways
were identified to be associated with COX5B. Besides respi-
ratory electron transport, oxidative phosphorylation (KEGG
data base), and electron transport chain (wiki pathways data
base) were most important (Table 4).
3.7. Western Blot Analysis and Confirmation of Expression.
The protein spot ID2494 (COX5B) was found in the previous
2D DIGE experiment to be significantly lower expressed in
the sample sepsis 48 h treatment compared to the samples
sepsis 24 h treatment and control. Between the samples
sepsis 24 h treatment and control, this protein spot was not
significantly differentially expressed.
Western Blot analysis of the three samples (separatedwith
1D SDS PAGE and transferred onto PVDF) was performed to
check whether the protein COX5B is differentially expressed.
After incubation with the anti-COX5B antibody a distinct
band at about 12 kDa was detected per lane (Figure 2(b)).
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15g load
Control 24h sepsis 48h sepsis
(a) Anti-alpha tubulin
15g load
Control 24h sepsis 48h sepsis
(b) Anti-COX5B
Figure 2: Enhanced chemiluminescence (ECL) signal of Western Blot analysis of anti-alpha tubulin (a) which was used as control and of
anti-COX5B (b). The anti-tubulin band is located at 55 kDa and the anti-COX5B band is located at 11 kDa. For analysis, 15 𝜇g load each was
used.
No cross-reactions or background signals were observed.
Corresponding to the SDS gel analysis, Western Blot analysis
also showed a decreased expression of COX5B at 48 hours
after sepsis.
As a loading control, the membrane was subsequently
incubated with anti-alpha tubulin antibody. A distinct band
at about 55 kDawas detected (Figure 2(a)). Following this, the
anti-COX5B antibody still gave a clear signal.
The image of the PVDF membrane after transfer and
Ponceau S total protein stain showed an even transfer and
only slightly different protein load for the three samples as
identified by anti-alpha tubulin analysis (Figure 2(a)).
4. Discussion
Our findings show differences in expression of several pro-
teins in the rat kidney during intermediate as well as late
stage sepsis. Of these proteins, COX5B in particular is of high
interest and linked to mitochondrial function and cellular
energy production [41]. During the course of sepsis, COX5B
was found to be less expressed by both MALDI-TOF and
Western Blot analysis in the late phase (i.e., after 48 hours)
as compared to the early phase of sepsis.
Proteomics has, during the last decade, increasingly
been applied to identify and quantify mitochondrial proteins
related to cellular perturbations [12]. So far, several dif-
ferent pathophysiological mechanisms have been proposed
for sepsis-induced AKI: vasodilation-induced glomerular
hypoperfusion, dysregulated circulation within the peritubu-
lar capillary network, inflammatory reactions by systemic
cytokine storm or local cytokine production, and tubular
dysfunction induced by oxidative stress [2].
4.1. CLP Model and Proteomics. There are still two funda-
mental problems inherently associated with studies of renal
responses to sepsis. First, difficult access to the renal tissue
and the associated ethical issues make the human research
into cellular and molecular biology in critically ill patients
with sepsis almost unfeasible [7]. Second, the process of
AKI in sepsis involves a complex of multiple dynamically
interacting factors and it is clear that both sepsis and septic
organ dysfunction are not caused by a single mechanism [7].
Therefore, experimental studies involving animal models are
fundamental to better define and characterize the pathophys-
iological phases of AKI [9].
We chose CLP model for sepsis because it is widely
accepted as one of the most close to the pathophysiologic
course of sepsis patient [42], it is easily feasible in small
animals [30], and it allows a suitable representation of gram-
negative sepsis [30]. The decision to analyze samples after
24 and 48 h reflects the evidence that clinical and laboratory
signs of sepsis become more conspicuous at 24 h [13, 30],
going from a hyperdynamic state (after 12 h) to a progressive
hypodynamic phase (after 16–24 h) or late stage (48 h) [30,
43–45].
4.2. Course of Sepsis: 24 versus 48 Hours after CLP. Figure 8
shows alterations in expression of the proteins analyzed
(Figure 8).Thehigher abundance ofMUP5 in control samples
and in intermediate compared to late sepsis samples could
suggest a kind of progressive downregulation of this protein
with the development of the kidney injury. COX5b also seems
to undergo a possible downregulation from intermediate to
late sepsis and was confirmed by the Western Blot analysis.
MYH6 andMYH7 appear to be the only upregulated proteins
during the late stage of sepsis-induced kidney injury.
Cytochrome c oxidase (COX, Complex IV) is a mito-
chondrial electron transport chain enzyme that resides in the
mitochondrial inner membrane, and its activity is required
to generate the proton motive force that drives downstream
ATP synthesis (Figure 7) [46]. It is one of the mitochondrial
isoforms of cytochrome c oxidase, that is, the Complex IV
of the mitochondrial respiratory chain (Table 6). COX5B is
involved in the final step of the oxidative phosphorylation,
with the production of H
2
O, and the maintenance of the
electrochemical gradient needed to produce ATP. It has been
shown that COX5B is implicated in the production of reactive
oxygen species (ROS) and nitric oxide (NO) in hypoxic or
anoxic conditions in both mammalian and yeast cells [47–
50]. ROS can lead to mitochondrial dysfunction, and this
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Figure 3: Protein network identified by STRING software (http://www.string-db.org/; confidence view, for MUP5, COX5b, MYH6, and
MYH7). Thickness of the lines is directly proportional to the strong of connections among the nodes. Medium level of confidence (score
0.400, with the maximum level of confidence at 0.900 and the lowest at 0.150) and no more than 20 nodes used. For other proteins in the
network, see Table 5. To generate the network, all significantly altered proteins were used for analysis, that is, pooled data from the 24 and 48
hours’ group.
condition, with NO overexpression, antioxidant depletion,
and reduction of ATP concentration, was found in skeletal
muscle cells of sepsis human patients [51] and rats [52].
Association of COX5B with the kidney is not completely
new. Tuma et al. also found COX5B being present in the
porcine kidney, in both cortex and medulla [6]. Although
this study did not analyze proteome alterations during sepsis
and in piglets, it showed the importance of COX5B in the
kidney. Fedorova et al. foundCOX4 less expressed in the five-
sixth nephrectomymodel of chronic renal failure of rats [53].
Expression of COX5B has also been shown to be associated
with hypoxia and a low oxygen environment [41].
PGC-1𝛼 (peroxisome proliferator-activated receptor-𝛾-
coactivator-1𝛼) is a member of a small family of tran-
scriptional regulators that controls the expression of genes
involved in energy homeostasis, mitochondrial biogenesis,
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Figure 4: GeneMANIA network (http://www.genemania.org/; visualization using Cytoscape, http://www.cytoscape.org/) found by search of
significantly regulated proteins of the present study (i.e., MYH6, MYH7, COX5B, and MUP5). Proteins were entered to gather interactions.
Green squares represent searched proteins and blue squares represent connections found by GeneMANIA. The identified proteins MUP5,
COX5B,MYH6, andMYH7 are linked togetherwithin this networkmainly byAtp5g1, COX5a, andOBP3.The lines show interactions between
the nodes/proteins. To generate the network, all significantly altered proteins were used for analysis, that is, pooled data from the 24 and 48
hours’ group.
fatty acid oxidation, and glucose metabolism [54]. PGC-1𝛼
is pivotal for the mitochondrial function, as well as for the
expression of key mitochondrial proteins [54]. Downregula-
tion of PGC-1𝛼 has been observed in different experimental
models of AKI, and it is implicated as a causative event in
renal functional impairment during sepsis-associated AKI
[54]. Furthermore, expression of COX5B is regulated by
PGC-1𝛼 [54] and both proteins should be downregulated
during emerging kidney injury. It may be speculated that
sepsis with consecutive hypotension, altered perfusion, and
possible hypoxia could have a comparable effect on COX5B
expression.
However, this link between COX5B and PGC-1𝛼 does
not demonstrate validity or superiority of one protein in the
context of a biomarker. Future studies should focus on the
usefulness of both molecules as biomarkers in AKI.
4.3. MYH6 and MYH7. Myosin presence has been dem-
onstrated in kidney descending vasa recta and in renal
arterioles and could be involved in the regulation of the
blood flow from descending vasa recta to capillary beds [55].
Myosin expressed in nonmuscle tissues plays a central role
in cell adhesion, migration, and division [9]. Some other
research revealed that MYL12A and MYL12B are crucial for
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Figure 5: Protein network created by PCViz (Pathway Commons; http://www.pathwaycommons.org/; visualization using Cytoscape,
http://www.cytoscape.org/). MYH6 and MYH7 are marked in green. All related proteins (blue nodes) are linked by lines to generate the
network. COX5B and MUP5 proteins were not found to be present in this specific network. To generate the network, all significantly altered
proteins were used for analysis, that is, pooled data from the 24 and 48 hours’ group.
maintenance of the stability of MYH9, MYH10, and
MYL6, which leads to normal cell actomyosin function
[9].
It has been reported thatmyosin is implicated in endothe-
lial barrier signaling [56]. Therefore, findings of the present
study show that expression of myosin is altered during sepsis
and could be a possible explanation for developing acute
kidney injury during sepsis. However, it is not clear from
the present point of view if the identified myosin originates
from the kidney or was retained from filtration by the sepsis-
injured kidney but was expressed elsewhere in the body.
Furthermore, human skeletal muscle cells exposed to plasma
of septic shock patients undergo a muscle protein loss with
reduction of myosin, mostly in the early phase of sepsis [57].
4.4. MUP5. Also named as “alpha 2-U globulin,” “alpha 2
euglobulin” is a rat protein synthetized in the liver, excreted
via the kidneys and reabsorbed by up to 60% by the proximal
tubule cells [58]. It is a precursor of a kidney fatty acid-
binding protein, involved in mechanism of binding and
transport of fatty acids (http://www.uniprot.org/) and it is
overexpressed in renal cortex rather than medulla [59]. This
protein can strongly bind toxic agents like alkans [58, 60] and
is associated with the accumulation of hyaline droplet that
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Table 6: Pathways associated with COX5B (from: http://www
.genecards.org/).
Pathway Database origin
Electron transport chain Wiki pathways
Oxidative phosphorylation Wiki pathways
Respiratory electron
transport, ATP synthesis by
chemiosmotic coupling,
and heat production by
uncoupling proteins
Reactome
The citric acid (TCA) cycle
and respiratory electron
transport
Reactome
Formation of ATP by
chemiosmotic coupling Reactome
Parkinson’s disease KEGG
Huntington’s disease KEGG
Oxidative phosphorylation KEGG
leads to damage of the proximal tubular epithelium and renal
cancer [61, 62].
In our sample, MUP5 spot was localized at a significantly
more alkaline pI than the other analyzed protein spots fea-
turing this protein, suggesting some kind of posttranslational
modification and/or degradation of MUP5 between 24 h and
48 h of sepsis.
4.5. Mitochondrial Dysfunction during Sepsis. Attempts to
understand the regulation of cellular energy production in
eukaryotic cells have focused on the components of the
mitochondrial respiratory chain and its three sites of energy
conservation [63]. Per milligram of tissue, only the heart
exceeds the kidney’s abundance of mitochondria [64]. The
healthy nephron relies on mitochondrially generated ATP in
order to facilitate the sodium-coupled reclamation of 99%
filtered water [64]. Mitochondrial oxidative phosphorylation
is responsible for over 90%of total body oxygen consumption
and ATP generation. Segments of the nephron that perform
themost chemical work are the proximal tubule and the thick
ascending limb of Henle’s loop [64].
The respiratory chain (electron-transport chain) includes
four individual enzyme complexes (I–IV). These enzyme
complexes, notably NADH-ubiquinone oxidoreductase
(complex I) and cytochrome C oxidase (complex IV), can
be inhibited by reactive oxygen and nitrogen species such as
nitric oxide [5].
Cytochrome c oxidase is a key enzyme in the overall
regulation of cellular energy production in eukaryotes [63].
Investigation into the underlying cellular mechanisms of
AKI increasingly points towards a predominant role of
mitochondria [7].
Ultrastructural changes in mitochondria are observed
in kidney tubular cells during ischemic nephrotoxic, as
well as sepsis-associated AKI, and result in functional
decreases [64]. The changes include decreased mitochon-
drial mass, disruption of cristae, and extensive mito-
chondrial swelling [64]. These changes in mitochondria
are often associated with functional decreases [64]. Mito-
chondrial dysfunction is, furthermore, also known as an
important pathogenic factor in sepsis-associated multior-
gan failure, including septic AKI [64]. It is noteworthy
that the mitochondria-centered structural and metabolic
or bioenergetic alterations occur prior to the onset of
AKI, supporting a causative, pathogenic role of mitochon-
drial damage in this disease condition [64]. Taking into
account these aspects, alterations in mitochondrial proteome
could serve as potential biomarkers for sepsis-associated
AKI.
Mitochondrial injury clearly arises in human sepsis, too,
as evidenced by biochemical and structural studies on tissue
biopsies obtained in intensive care settings [64]. Despite
the recognition of mitochondrial dysfunction in AKI, the
underlying mechanism is largely unclear [64]. Using the
methodology of the present study, it can give additional
insight into affected signaling cascades or tissue pathways.
Mitophagy has also been described for the kidney in the
course of sepsis [65].
4.6. AKI in the Context of the Present Study. In 2012, Hsiao et
al. demonstrated a biphasic change of autophagy in the septic
AKI (SAKI)model of CLP in rats [66]. Autophagywas shown
to elevate at hours but then declined at 9 hours following CLP,
where AKI was detected at 18 hours [64].
A considerable number of novel biomarkers for SAKI
were developed during recent years and tested in clinical
trials, such as cystatin c, neutrophil gelatinase-associated
lipocalin (NGAL), interleukin-18 (IL-18), kidney injury
molecule-1 (KIM-1), and liver-type fatty acid-binding protein
(L-FABP); however, very little of value for earlier prognos-
tication has transpired to date [9]. Therefore, screening of
ideal biomarkers with highly sensitivity and specificity for
AKI becomes very important and urgent [9]. Besides sepsis,
also cis-platin-induced loss of renal function has been shown
to be associated with a decreased expression of COX activity
[64].
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4.7. Study Limitations. There are some limitations of the
present study which should be clearly addressed. First,
validity of CLP model can be critically discussed. We used
a standardized approach to induce sepsis and to get stable
mortality rates. However, it is not completely clear to what
extent rats suffered from acute kidney injury. Second, pro-
teomics as molecular technique has some limitations itself,
for example, problematic identification of low-abundant pro-
teins. Analysis was performed standardized with the highest
level of quality possible. But, it may be possible that other
relevant proteins exist not being identified with the technique
used. Third, due to the complex experimental setting and
extensive techniques used, the number of rats used seems
low. However, standardized approaches were implemented to
minimize interrat variations as effective as possible. Fourth, it
would be helpful to study the course of COX5B expression in
both serum and urine at specific time points. However, since
we did not collect urine, we have to refer to future studies
to answer this question. Finally, we performed proteomics to
identify altered tissue proteins. Therefore, interpretation of
these results has to be careful and it has to take into account
the fact that unknown mechanisms or protein interactions
could exist.
5. Conclusions and Future Aspects
The present study analyzed proteome alterations in rat tissue
during sepsis to identify possible biomarker candidates in
the tissue. In summary, our study combines the power of
proteomics with a classic animal model of sepsis.
COX5B could be a promising biomarker candidate since a
significant association was found during experimental sepsis
in the present study. For future research, COX5B should be
evaluated as a biomarker in both human urine and serum
to identify sepsis. Furthermore, it might be very interesting
to compare this possible biomarker to other already known
biomarkers for AKD, for example, PGC1𝛼 [8]. Unfortunately,
it was not the focus of the present study to compare different
biomarkers for AKD/AKI but future studies may focus on
practicability and usability of different biomarkers in septic
patients to find optimal and valid biomarkers.
In the future, it would be highly advantageous to identify
biomarkers present in the urine or serumwhich would reveal
AKD very early in its course [29] and to stratify patients and
identify patients at risk for AKI. If the renal disease would
be detected at a very early stage, reversal or cure might be
possible [29].
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